MX9709869A - Derivados de dieteres de catecol utiles, composiciones farmaceuticas que los contienen, y uso de los mismos. - Google Patents

Derivados de dieteres de catecol utiles, composiciones farmaceuticas que los contienen, y uso de los mismos.

Info

Publication number
MX9709869A
MX9709869A MX9709869A MX9709869A MX9709869A MX 9709869 A MX9709869 A MX 9709869A MX 9709869 A MX9709869 A MX 9709869A MX 9709869 A MX9709869 A MX 9709869A MX 9709869 A MX9709869 A MX 9709869A
Authority
MX
Mexico
Prior art keywords
pharmaceutical agents
derivatives useful
pde
tnf
compound
Prior art date
Application number
MX9709869A
Other languages
English (en)
Other versions
MXPA97009869A (es
Inventor
Allen J Duplantier
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9709869A publication Critical patent/MX9709869A/es
Publication of MXPA97009869A publication Critical patent/MXPA97009869A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto de formula (Ver Formula); en la que a, b, V, W, X, Y, Z, R1 y R2 son como se ha definido anteriormente. Los compuestos de la formula I, y las sales farmacéuticamente aceptables de la misma, son de utilidad para la inhibicion de la fosfodiesterasa (PDE) tipo IV y de la produccion de factor de necrosis tumoral (TNF), y en el tratamiento del asma, artritis, bronquitis, enfermedad cronica obstructiva de las vías respiratorias, psoriasis, rinitis alérgica, dermatitis y otras enfermedades inflamatorias caracterizadas por tener actividad de fosfodiesterasa (PDE) tipo IV, así como SIDA, sepsis, choque séptico y otras enfermedades, tales como la caquexia, que impliquen la produccion de TNF.
MXPA/A/1997/009869A 1995-06-07 Derivados de dieteres de catecol utiles,composiciones farmaceuticas que los contienen, yuso de los mismos MXPA97009869A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1995/007208 WO1996040636A1 (en) 1995-06-07 1995-06-07 Catechol diethers derivatives useful as pharmaceutical agents

Publications (2)

Publication Number Publication Date
MX9709869A true MX9709869A (es) 1998-03-31
MXPA97009869A MXPA97009869A (es) 1998-10-15

Family

ID=

Also Published As

Publication number Publication date
FI114468B (fi) 2004-10-29
ES2193196T3 (es) 2003-11-01
CA2223245A1 (en) 1996-12-19
EP0869945B1 (en) 2003-04-16
PT869945E (pt) 2003-09-30
JP2001527508A (ja) 2001-12-25
FI974442A0 (fi) 1997-12-05
DE69530429D1 (de) 2003-05-22
US6028086A (en) 2000-02-22
JP3410104B2 (ja) 2003-05-26
EP0869945A1 (en) 1998-10-14
ATE237589T1 (de) 2003-05-15
DK0869945T3 (da) 2003-07-14
FI974442A (fi) 1997-12-05
WO1996040636A1 (en) 1996-12-19
CA2223245C (en) 2002-05-21
DE69530429T2 (de) 2003-10-30

Similar Documents

Publication Publication Date Title
CA2166721A1 (en) Bicyclic tetrahydro pyrazolopyridines
MX9504422A (es) Tetrahidropirazolopiridinas biciclicas.
DE69410121D1 (en) Dihydro pyrazolopyrrole
CA2176506A1 (en) Substituted Oxindoles
CA2150812A1 (en) Catechol diethers as selective pde iv inhibitors
NO980313L (no) N-(aroyl)glysin-hydroksaminsyre-derivater og beslektete forbindelser
MY116527A (en) Tricyclic 5, 6-dihydro-9h-pyrazolo [3,4,-c]-1,2,4- triazolo [4,3-a] pyridines
CA2258285A1 (en) Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
YU11299A (sh) Derivati indazola
ATE370138T1 (de) Neue imidazopyridine und ihre verwendung
CA2252982A1 (en) Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
WO2005037825A3 (en) Protein kinase inhibitors
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
CA2223245A1 (en) Catechol diethers derivatives useful as pharmaceutical agents
BG108426A (en) Novel sulfonic acid derivatives
EP1036078A1 (de) Thienopyrimidine
JP2006512293A5 (es)
EP1210349A2 (de) Pyrazolo[4, 3-d]pyrimidine
EP1357904A2 (de) Verwendung von pyrazolo 4,3-d]pyrimidinen
WO2002045716A1 (de) Verwendung von pyrazolo[4,3-d]pyrimidinen
US5753691A (en) Agents for inhibiting the production of IL-1β and the release of TNFα